Clinical trials: Breast Cancer, Metastatic
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer.
- Trial name
- TRIBECA (NCT02064829)
- Testing
- Nab-paclitaxel, IG-001
- Where
- 20 sites in United States, Georgia and 5 more
- Volunteers
- 111 people
- Sponsor
- Sorrento Therapeutics, Inc.
Metastatic Breast Cancer
Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey
This study is planned as a secondary data use (SDU) study and the data collection will be performed retrospectively. Patients who presented to the participating sites with metastatic breast cancer will be defined, and patients'…
- Trial name
- NCT04770129
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 1,331 people
- Sponsor
- Turkish Oncology Group
Breast Cancer Lung Metastasis
Evaluation of a Genetic Risk Score for Lung Metastasis and Prognosis in Breast Cancer
The goal of this observational study is to validate the predictive ability of a six-gene risk score model for lung metastasis in patients with early-stage breast cancer.
- Trial name
- NCT07752966
- Testing
- Standard management
- Volunteers
- 330 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Neoplasms
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
The international treatment guidelines now include recommendations for the use of CDK 4/6 inhibitors in combination with hormone agents for the treatment of postmenopausal women with hormone-receptor-positive/HER2-negative ABC as…
- Trial name
- NCT04858997
- Testing
- Palbociclib, AI
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
This multicenter, open-label dose-escalation study with an extension phase will evaluate the safety and pharmacokinetics of lumretuzumab in combination with pertuzumab and paclitaxel in participants with metastatic breast cancer…
- Trial name
- NCT01918254
- Testing
- Paclitaxel, Pertuzumab, Lumretuzumab
- Where
- 13 sites in Denmark, France and 2 more
- Volunteers
- 66 people
- Sponsor
- Hoffmann-La Roche
Triple-negative Breast Cancer, Bone Metastases
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
The goal of this clinical trial is to learn if Tislelizumab Combined with Nab-Paclitaxel works to treat patients of TNBC with bone metastasis as first line treatment. It will also learn about the safety of the combination.
- Trial name
- NCT06538896
- Testing
- Tislelizumab + Nab-Paclitaxel, Rankl inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Breast Cancer, ER-positive Breast Cancer
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
The objective of this trial, DBCG R25, will be to evaluate the effect of trastuzumab-deruxtecan versus standard of care on progression-free survival (PFS) in first-line for patients with non-Luminal A, ER-positive/HER2-negative…
- Conditions
- Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched
- Trial name
- DISCORDANT (NCT06585969)
- Testing
- Trastuzumab deruxtecan (T-DXd), Ribociclib with ET, Abemaciclib with ET
- Sponsor
- Danish Breast Cancer Cooperative Group
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations
- Trial name
- NCT05363605
- Testing
- [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
- Where
- 6 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
This study is an open, multicenter, prospective phase I dose escalation clinical trial followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2 Dose (R2PD) and the safety profile, among other…
- Trial name
- ROGABREAST (NCT04483505)
- Testing
- Combination, Rogaratinib + palbociclib + fulvestrant
- Where
- 8 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Advanced or Metastatic Breast Cancer (BC)
Trans-RosaLEE Study: a Biomarker-directed, Translational Study
Hormone receptor (HR)-positive and HER2-negative (HR+/HER2-) metastatic/advanced breast cancer (mBC) is a major public health issue.
- Trial name
- TransRosaLEE (NCT05529862)
- Testing
- Pre-treatment biopsy, Post treatment biopsy, Pre treatment blood sampling
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Institut Paoli-Calmettes
Breast Neoplasm
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
The primary purpose of the study is to examine the safety and effectiveness of combination therapy consisting of daily oral capecitabine and weekly intravenous vinorelbine in stage IV breast cancer subjects.
- Trial name
- NCT00194727
- Testing
- Vinorelbine, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Ovarian Neoplasms, Breast Neoplasms
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or…
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Paresthesia
- Trial name
- NCT00746694
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or…
- Trial name
- NCT06851442
- Testing
- TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
- Where
- 17 sites in China
- Volunteers
- 8 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
The H3RAKLES trial would allow patients with a progressive metastatic breast cancer to have access to one more line of systemic therapy.
- Trial name
- H3RAKLES (NCT07193394)
- Testing
- Tucatinib (ONT-380), Trastuzumab (Herceptin)
- Where
- 9 sites in France
- Volunteers
- 20 people
- Sponsor
- Institut Curie
Breast Cancer, Metastatic
Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,
Development and validation of an integrated testing strategy for simultaneous detection of ESR-1 and gBRCA mutations via liquid biopsy in HR+/HER2- metastatic breast cancer (mBC) patients, and the creation of a digital gene…
- Trial name
- L2-268 (NCT06762483)
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- European Institute of Oncology
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1)
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
This is a research study in 2 parts assessing the following parameters of the combination of the study drug called bosutinib, and a drug called capecitabine: the safety, how well the subject's body handles the study drug, and…
- Conditions
- Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1)
- Trial name
- NCT00959946
- Testing
- Bosutinib, Capecitabine
- Where
- 7 sites in United States, Australia and 4 more
- Volunteers
- 32 people
- Sponsor
- Pfizer
Metastatic Breast Cancer With HER2 Positive, Triple Negative Breast Cancer
Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer
In general, brain metastases found after development of neurologic symptoms have poor prognosis. Therefore, the investigators aim to investigate whether regular brain MRI (Magnetic Resonance Imaging) can detect early brain…
- Trial name
- NCT03617341
- Testing
- Brain MRI
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.